<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04923074</url>
  </required_header>
  <id_info>
    <org_study_id>2020-162</org_study_id>
    <nct_id>NCT04923074</nct_id>
  </id_info>
  <brief_title>the Application of Diffusion Tensor Imaging in the Evaluation of Peripheral Neuropathy in ANCA Associated Vasculitis</brief_title>
  <official_title>the Application of Diffusion Tensor Imaging(DTI) in the Evaluation of Peripheral Neuropathy in Anti-neutrophil Cytoplasmic Antibodies Associated Vasculitis(AAV)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Include qualified 50 ANCA-associated vasculitis(AAV) patients; and the first 27 patients&#xD;
           will be divided into 3 groups with different diffused tension image (DTI) parameters and&#xD;
           to choose the best strategy；&#xD;
&#xD;
        2. On baseline, 6 months after treatment and 24 months after treatment, the AAV patients&#xD;
           will accomplish the Birming-ham vasculitis activity score(BVAS) besides DTI；&#xD;
&#xD;
        3. The new serum biomarkers of AAV associated peripheral neuropathy will be measured by&#xD;
           ELISA； (4) Another cohort with 50 patients with AAV associated peripheral neuropathy who&#xD;
           were evaluated by traditional methods (electromyogram) and compared to the patients&#xD;
           cohort that evaluated using DTI by cost-benefit analysis&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">July 2021</start_date>
  <completion_date type="Anticipated">July 2023</completion_date>
  <primary_completion_date type="Anticipated">July 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the optimal b-value (a key parameter) for DTI in AAV associated peripheral neuropathy</measure>
    <time_frame>2 years</time_frame>
    <description>b-value is a key technique parameter for DTI, which will decide the quality of DTI image</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>the association between normative diffusion value of DTI (FA and ADC value) and disease activity activity score of AAV (BVAS).</measure>
    <time_frame>2 years</time_frame>
    <description>Birmingham Vasculitis Activity Score (BVAS) is a index of vasculitis disease activity, with the score range 0-63. Fractional anisotropy(FA) and apparent diffusion coefficient(ADC) are two parameters that can be read through DTI image .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>the association between normative diffusion value of DTI (FA and ADC value) and serum biomarkers of AAV associated neuropathy</measure>
    <time_frame>2 years</time_frame>
    <description>sCD163, Nfl（neurofilament light polypeptide）and OPN（osteopontin）are new biomarkers of peripheral neuropathy</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>ANCA Associated Vasculitis</condition>
  <arm_group>
    <arm_group_label>DTI group</arm_group_label>
    <description>the patient in this group will receive DTI evaluation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>routine group</arm_group_label>
    <description>the patient in this group will receive routine evaluation</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>diffusion tensor imaging(DTI) evaluation</intervention_name>
    <description>DTI is a new kind of MRI technique to evaluate peripheral neuropathy</description>
    <arm_group_label>DTI group</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        adult AAV patients with peripheral neuropathy&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  age between 18-80 years old；&#xD;
&#xD;
          -  must fulfill 2012 criteria of ANCA associated vasculitis&#xD;
&#xD;
          -  presented with peripheral neuropathy diagnosed by specialists&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  the ANCA associated vasculitis is already in the stable stage after treatments&#xD;
&#xD;
          -  any vital organ dysfunction&#xD;
&#xD;
          -  active infection or cancer&#xD;
&#xD;
          -  can not finish DTI scan&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Jing Xue</last_name>
    <role>Study Chair</role>
    <affiliation>2nd affiliated hospital of Zhejiang University, School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>wenjia sun</last_name>
    <phone>86 15869029727</phone>
    <email>sunwinjoy@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>ting zhang</last_name>
    <phone>86 15888819691</phone>
    <email>zhangtingpumc@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>2nd affiliated hospital of Zhejiang University, School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>wenjia sun</last_name>
      <phone>86 15869029727</phone>
      <email>sunwinjoy@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 1, 2021</study_first_submitted>
  <study_first_submitted_qc>June 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 11, 2021</study_first_posted>
  <last_update_submitted>June 5, 2021</last_update_submitted>
  <last_update_submitted_qc>June 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 11, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>peripheral neuropathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Vasculitis</mesh_term>
    <mesh_term>Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

